SEARCH

SEARCH BY CITATION

References

  • 1
    Rustin GJ,Marples M,Nelstrop AE, et al. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol. 2001; 19: 4054-4057.
  • 2
    Rustin GJ,Timmers P,Nelstrop A, et al. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol. 2006; 24: 45-51.
  • 3
    Bridgewater JA,Nelstrop AE,Rustin GJ, et al. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol. 1999; 17: 501-508.
  • 4
    Vergote I,Rustin GJ,Eisenhauer EA, et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst. 2000; 92: 1534-1535.
  • 5
    Vergote IB,Bormer OP,Abeler VM. Evaluation of serum CA 125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol. 1987; 157: 88-92.
  • 6
    Makar AP,Kristensen GB,Bormer OP, et al. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy. Gynecol Oncol. 1993; 49: 73-79.
  • 7
    Peters-Engl C,Obermair A,Heinzl H, et al. CA 125 regression after 2 completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer. Br J Cancer. 1999; 81: 662-666.
  • 8
    Markman M,Liu PY,Rothenberg ML, et al. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol. 2006; 24: 1454-1458.
  • 9
    Santillan A,Garg R,Zahurak ML, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005; 23: 9338-9343.
  • 10
    McGuire WP,Hoskins WJ,Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996; 334: 1-6.
  • 11
    Markman M,Bundy BN,Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001; 19: 1001-1007.
  • 12
    Muggia FM,Braly PS,Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000; 18: 106-115.
  • 13
    Rose PG,Nerenstone S,Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004; 351: 2489-2497.
  • 14
    Ozols RF,Bundy BN,Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003; 21: 3194-3200.
  • 15
    Armstrong D,Bundy BN,Walker J, et al. A phase III randomized trial of intravenous paclitaxel and cisplatin versus intravenous paclitaxel, intraperitoneal cisplatin and intraperitoneal paclitaxel in patients with optimal stage III epithelial ovarian carcinoma or primary peritoneal carcinoma. N Engl J Med. 2006; 354: 34-43.
  • 16
    Spriggs DR,Brady MF,Rubin S, et al. A phase III randomized trial of cisplatin and paclitaxel administered by either 24 hour or 96 hour infusion in patients with selected stage III or stage IV epithelial ovarian cancer (GOG162). J Clin Oncol. 2007; 25: 4466-4471.
  • 17
    Omura GA,Brady MF,Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology experience. J Clin Oncol. 1991; 9: 1138-1150.
  • 18
    Winter WE,Maxwell GL,Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group (GOG) study. J Clin Oncol. 2007; 25: 3621-3627.
  • 19
    Pectasides D,Fountzilas G,Aravantinos G, et al. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2005; 97: 436-441.
  • 20
    Hess V,A'Hern R,Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004; 22: 1040-1044.
  • 21
    Goff BA,Sainz de la CR,Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol. 1996; 60: 412-417.
  • 22
    Crotzer DR,Sun CC,Coleman RL, et al. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol. 2007; 105: 404-408.
  • 23
    Lu KH,Patterson AP,Wang L, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 2004; 10: 3291-3300.
  • 24
    Hogdall EV,Christensen L,Kjaer SK, et al. CA-125 expression pattern, prognosis and correlation with serum CA-125 in ovarian tumor patients. From The Danish “MALOVA” Ovarian Cancer Study. Gynecol Oncol. 2007; 104: 508-515.
  • 25
    Redman JR,Petroni GR,Saigo PE,Geller NL,Hakes TB. Prognostic factors in advanced ovarian carcinoma. J Clin Oncol. 1986; 4: 515-523.
  • 26
    Eisenkop SM,Friedman RL,Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998; 69: 103-108.
  • 27
    Zorn KK,Armstrong DK,Tian C, et al. Significance of pretreatment CA-125 level in advanced ovarian carcinoma: a meta-analysis of 7 Gynecologic Oncology Group protocols [abstract]. Gynecol Oncol. 2007; 104: S3.